Novo Nordisk A/S vs Shell PLC — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Shell PLC trades at $87.12 (market cap $235.24B). The key difference: Novo Nordisk A/S and Shell PLC are close in size by market cap, and Shell PLC is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SHEL | |
|---|---|---|
Market Cap | $220.53B | $235.24B |
Sector | Health | Energy |
52-Week High | $71.70 | $94.15 |
52-Week Low | $35.29 | $70.31 |
Enterprise Value | $239.49B | $287.77B |
Dividend Yield | 3.63% | 3.63% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →